share_log

6-K: Report of foreign private issuer [Rules 13a-16 and 15d-16]

6-K: Report of foreign private issuer [Rules 13a-16 and 15d-16]

6-K:外國發行人報告
美股SEC公告 ·  06/13 08:33
Moomoo AI 已提取核心訊息
Alterity Therapeutics, a biotechnology company specializing in treatments for neurodegenerative diseases, announced that its CEO, David Stamler, M.D., will present at the MST Access 'Hidden Gems in Life Sciences' webinar. The presentation is scheduled for June 13, 2024, in Australia and June 12, 2024, in the United States. The company, which is in the clinical stage of developing its lead asset, ATH434, for treating Parkinsonian disorders, will offer an overview of its operations and developments. Investors will have the opportunity to ask questions during the webinar, and a recording will be available on Alterity's website post-event. The announcement was authorized by CEO David Stamler and is part of a Form 6-K report filed with the SEC, which is also incorporated by reference into the company's various registration statements.
Alterity Therapeutics, a biotechnology company specializing in treatments for neurodegenerative diseases, announced that its CEO, David Stamler, M.D., will present at the MST Access 'Hidden Gems in Life Sciences' webinar. The presentation is scheduled for June 13, 2024, in Australia and June 12, 2024, in the United States. The company, which is in the clinical stage of developing its lead asset, ATH434, for treating Parkinsonian disorders, will offer an overview of its operations and developments. Investors will have the opportunity to ask questions during the webinar, and a recording will be available on Alterity's website post-event. The announcement was authorized by CEO David Stamler and is part of a Form 6-K report filed with the SEC, which is also incorporated by reference into the company's various registration statements.
生物技術公司Alterity Therapeutics專注於神經退行性疾病的治療,宣佈其首席執行官David Stamler博士將在MST Access“生命科學中的隱藏寶石”網絡研討會上發表演講。演講將於2024年6月13日在澳洲和2024年6月12日在美國舉行。該公司正在臨床階段開發其主導資產ATH434,用於治療帕金森症性障礙,並將概述其運營和發展狀況。投資者將有機會在網絡研討會期間提問,並在活動後通過Alterity的網站獲取演講錄音。該公告得到了首席執行官David Stamler的授權,並被列入提交給SEC的6-K表格報告的一部分,該報告也被納入公司的各種註冊聲明中。
生物技術公司Alterity Therapeutics專注於神經退行性疾病的治療,宣佈其首席執行官David Stamler博士將在MST Access“生命科學中的隱藏寶石”網絡研討會上發表演講。演講將於2024年6月13日在澳洲和2024年6月12日在美國舉行。該公司正在臨床階段開發其主導資產ATH434,用於治療帕金森症性障礙,並將概述其運營和發展狀況。投資者將有機會在網絡研討會期間提問,並在活動後通過Alterity的網站獲取演講錄音。該公告得到了首席執行官David Stamler的授權,並被列入提交給SEC的6-K表格報告的一部分,該報告也被納入公司的各種註冊聲明中。
声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息